Tekmira suspends work on its Ebola drug; Changes its name

Published On 2015-07-22 08:51 GMT | Update On 2015-07-22 08:51 GMT

Tekmira Pharmaceuticals Corp will stop the work on its Ebola drug as it not confident of passing through the clinical trial of the product

A Canada-based pharmaceutical company, Tekmira has announced its intention to discontinue the work of its drug for Ebola virus and change its name. The decision comes in the consideration of the company stating that the experimental drug for Ebola will fail to get the clearance in the clinical trial test. The company will change its name to Arbutus Biopharma Corp, and instead focus on experimental treatments for the hepatitis B virus.

At present, the company is focused to get atleast four drug approvals for clinical development in early next year. Tekmira said the new name reflects its combination with OnCore BioPharma, which it bought in March. The company says the name change will take effect by Aug. 3. Its ticker symbol will become "ABUS.", as reported by AP.

Tekmira's experimental drugs were used in at least one patient in 2014 as an Ebola epidemic spread through several West African nations and the search for more effective treatments kicked into high gear. Other companies in the field included NewLink Genetics Corp., Inovio Pharmaceuticals Inc., GlaxoSmithKline PLC and Allergan PLC's MAPP Pharmaceuticals unit.

Shares of Tekmira jumped after the OnCore deal was announced in January, but since the end of that month they have fallen 56 percent.

Its U.S. shares fell 10 cents to close at $11.18 on Monday. Its shares have risen more than 19 percent over the past year.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She is a member of the Association of Healthcare Journalists. She can be contacted at meghna@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Tekmira suspends work on its Ebola drug; Changes its name

Similar News

India conferred with Bloomberg Philanthropies Global Tobacco Control Award

LIC eyes entry into health insurance space by month end

Meerut doctor, 3 Touts arrested for illegal sex determination test

RG Kar Financial Irregularities Case: Court Reprimands CBI for Failing to Provide Documents

World Leprosy Day 2025: WHO urges Governments to focus on Leprosy elimination

Doctor killed, another injured as car plunges into canal in Ballia

Dera Followers Castration Case: Punjab and Haryana HC Rejects Doctor's Plea to Waive Bail Conditions

Telangana Medical Council warns Public against Illegal Online Lab Tests